Neuropsychiatric adverse effects of centrally acting antiobesity drugs
- PMID: 21951371
- PMCID: PMC6493804
- DOI: 10.1111/j.1755-5949.2010.00172.x
Neuropsychiatric adverse effects of centrally acting antiobesity drugs
Abstract
Introduction: Central neurochemical systems including the monoamine, opioid, and cannabinoid systems have been promising targets for antiobesity drugs that modify behavioral components of obesity. In addition to modulating eating behavior, centrally acting antiobesity drugs are also likely to alter emotional behavior and cognitive function due to the high expression of receptors for the neurochemical systems targeted by these drugs within the fronto-striatal and limbic circuitry.
Methods: This paper reviewed the neuropsychiatric adverse effects of past and current antiobesity drugs, with a central mechanism of action, linking the adverse effects to their underlying neural substrates and neurochemistry.
Results: Antiobesity drugs were found to have varying neuropsychiatric adverse event profiles. Insomnia was the most common adverse effect with drugs targeting monoamine systems (sibutramine, bupropion and tesofensine). These drugs had some positive effects on mood and anxiety and may have added therapeutic benefits in obese patients with comorbid depression and anxiety symptoms. Sedation and tiredness were the most common adverse effects reported with drugs targeting the m-opioid receptors (i.e., naltrexone) and combination therapies targeting the opioid and monoamine systems (i.e., Contrave™). Cognitive impairments were most frequently associated with the antiepileptic drugs, topiramate and zonisamide, consistent with their sedative properties. Drugs targeting the cannabinoid system (rimonabant and taranabant) were consistently associated with symptoms of anxiety and depression, including reports of suicidal ideation. Similar adverse events have also been noted for the D₁/D₅ antagonist ecopipam.
Conclusion: These findings highlight the need to assess neuropsychiatric adverse events comprehensively using sensitive and validated methods early in the clinical development of candidate antiobesity drugs with a central mechanism of action.
© 2010 Blackwell Publishing Ltd.
Conflict of interest statement
The authors have no conflict of interest.
Similar articles
-
[Pharmacological therapy of obesity].G Ital Cardiol (Rome). 2008 Apr;9(4 Suppl 1):83S-93S. G Ital Cardiol (Rome). 2008. PMID: 18773755 Italian.
-
Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials.Diabetes Obes Metab. 2017 Nov;19(11):1529-1536. doi: 10.1111/dom.12963. Epub 2017 Jul 21. Diabetes Obes Metab. 2017. PMID: 28386912 Free PMC article.
-
The cardiovascular safety of antiobesity drugs-analysis of signals in the FDA Adverse Event Report System Database.Int J Obes (Lond). 2020 May;44(5):1021-1027. doi: 10.1038/s41366-020-0544-4. Epub 2020 Mar 9. Int J Obes (Lond). 2020. PMID: 32152496
-
Drug safety evaluation of naltrexone/bupropion for the treatment of obesity.Expert Opin Drug Saf. 2014 Jun;13(6):831-41. doi: 10.1517/14740338.2014.909405. Epub 2014 Apr 28. Expert Opin Drug Saf. 2014. PMID: 24766397 Review.
-
[Obesity: a review of currently used antiobesity drugs and new compounds in clinical development].Postepy Hig Med Dosw (Online). 2007 Oct 19;61:612-26. Postepy Hig Med Dosw (Online). 2007. PMID: 17971763 Review. Polish.
Cited by
-
The Degree of Inulin Polymerization Is Important for Short-Term Amelioration of High-Fat Diet (HFD)-Induced Metabolic Dysfunction and Gut Microbiota Dysbiosis in Rats.Foods. 2024 Mar 28;13(7):1039. doi: 10.3390/foods13071039. Foods. 2024. PMID: 38611345 Free PMC article.
-
Cannabinoids, Endocannabinoids, and Synthetic Cannabimimetic Molecules in Neuromuscular Disorders.Int J Mol Sci. 2023 Dec 23;25(1):238. doi: 10.3390/ijms25010238. Int J Mol Sci. 2023. PMID: 38203407 Free PMC article. Review.
-
Notifications and Health Consequences of Unauthorized Pharmaceuticals in Food Supplements.Pharmacy (Basel). 2023 Sep 23;11(5):154. doi: 10.3390/pharmacy11050154. Pharmacy (Basel). 2023. PMID: 37888499 Free PMC article.
-
The function of the endocannabinoid system in the pancreatic islet and its implications on metabolic syndrome and diabetes.Islets. 2023 Dec 31;15(1):1-11. doi: 10.1080/19382014.2022.2163826. Islets. 2023. PMID: 36598083 Free PMC article.
-
Quality of life outcomes in two phase 3 trials of setmelanotide in patients with obesity due to LEPR or POMC deficiency.Orphanet J Rare Dis. 2022 Feb 5;17(1):38. doi: 10.1186/s13023-022-02186-z. Orphanet J Rare Dis. 2022. PMID: 35123544 Free PMC article. Clinical Trial.
References
-
- Moore ME, Stunkard A, Strole L. Obesity, social class, and mental illness. JAMA 1962;181:962–966. - PubMed
-
- Istvan J, Zavela K, Weidner G. Body weight and psychological distress in NHANES I. Int J Obes Relat Metab Disord 1992;16:999–1003. - PubMed
-
- Faith MS, Allison DB, Geiliebter A. Emotional eating and obesity: Theoretical considerations and practical recommendations In: Dalton S, editor. Overweight and weight management. The health professional's guide to understanding and practice. Gaithersburg , MD : Aspen Publishers, 1997;439–469.
-
- Hällström T, Noppa H. Obesity in women in relation to mental illness, social factors and personality traits. J Psychosom Res 1981;25:75–82. - PubMed
-
- Kittel F, Rustin RM, Dramaix M, de Backer G, Kornitzer M. Psycho‐socio‐biological correlates of moderate overweight in an industrial population. J Psychosom Res 1978;22:145–158. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous